Senseonics Announces Favorable Outcome of FDA Advisory Committee on the Eversense System

By |2018-04-02T14:46:00+00:00April 2nd, 2018|Uncategorized|

GERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced a favorable outcome of the U.S. Food and Drug Administration (FDA) Clinical Chemistry and Clinical Toxicology Devices meeting on the Eversense system. [...]